Bengaluru, October 13, 2015: Dermozone, the renowned Indonesia based herbal skin care products company, has announced its entry into the Indian market. The company has set up its office in Bengaluru in the name of Indo- Dermozone Herbal Pvt. Ltd.
Dermozone also announced the appointment of Mr Manjunatha K.G as Chief Operation Officer of Indo- Dermozone Herbal Pvt. Ltd, who would lead and oversee the Indian operations. Mr Manjunatha has over 27 years experience in technology and management and brings together entrepreneurial drive and vision with exceptional technology know-how to launch new products, build new competencies and penetrate lucrative market niches.
Dermozone is globally recognized for its wide range of herbal skin care products especially its flagship brand- MedCare Ozonated Olive Oil, primarily used for the treatment of Acne, Fungal Infections, Dry Skin, Insect Bites, Athlete’s Foot, Eczema, Blisters, Carbuncles, Diabetic Wounds, Burns, Cuts, Wounds and Vaginal Thrush.
“We are extremely excited about our plans to enter the Indian market and will be soon formally launching our flagship product MedCare Ozonated Olive Oil,” said Mr K.S Dharshan, Chairman and CEO of Dermozone. “After 14 years of extensive research, MedCare Ozonated Olive Oil has pioneered into a product that repairs, rejuvenates and refines your skin, keeping it in top condition. With the goodness of Mother Nature, used by people across the globe, MedCare heals wounds and solves your everyday skin problems.”
Headquartered in Indonesia, Dermozone also has operations in UK, USA, Japan, Russia, Seoul and China.
Corporate Comm India(CCI Newswire)
Pearson Syndrome is an extremely rare condition and the prevalence is approximately 1 in a…
A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…
People who smoke are also at much higher risk of developing diabetes compared to non-smokers…
17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…
Lonavala, November 12, 2024: As the global cancer burden rises to 30 million cases by…
The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…